Sugi Predict

Sugi Predict / Compounds / SCHEMBL10694524

SCHEMBL10694524

SCHEMBL10694524

CS(=O)(=O)c1ccc(N)c(Br)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 9/20 0.70
▸ CA1 P00915 8/20 0.70
▸ CA9 Q16790 8/20 0.70
▸ CA12 O43570 5/20 0.70
▸ CA4 P22748 4/20 0.70
▸ CA6 P23280 4/20 0.70
▸ CA5A P35218 4/20 0.70
▸ CA7 P43166 4/20 0.70
▸ CA14 Q9ULX7 4/20 0.70
▸ CA5B Q9Y2D0 4/20 0.70
▸ G6PD P11413 1/20 0.58
▸ IDE P14735 1/20 0.58
▸ CA3 P07451 1/20 0.43
▸ PKM P14618 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29948313 1.00 CA2 (0.70) CA2CA1CA9CA12CA4
SCHEMBL1006804 0.83 G6PD (0.53) CA2CA1CA9CA12CA4
SCHEMBL878968 0.83 CA2 (1.00) CA2CA1CA9CA12CA4
SCHEMBL2811342 0.83 CA2 (0.76) CA2CA1CA9CA12CA4
SCHEMBL30351262 0.83 CA2 (1.00) CA2CA1CA9CA12CA4
SCHEMBL4639254 0.81 G6PD (0.60) CA2CA1CA9CA12CA4
SCHEMBL898422 0.80 G6PD (0.64) CA2CA1CA9CA12CA4
SCHEMBL10688819 0.80 CA2 (0.66) CA2CA1CA9CA12CA4
SCHEMBL3434572 0.79 CA2 (0.70) CA2CA1CA9CA12CA4
SCHEMBL7769757 0.79 CA2 (0.70) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 — — US disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
US-11180487-B2 Substituted cyanoindoline derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-11-23 — — US disclosed
CN-108558889-B Bromodomain inhibitors 赛尔基因昆蒂赛尔研究公司 2021-11-05 — — CN disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 — — US disclosed
WO-2013138568-A1 LIVER X RECEPTION MODULATORS VITAE PHARMACEUTICALS, INC. (US) 2013-09-19 — — WO disclosed
WO-2013138568-A1 LIVER X RECEPTION MODULATORS VITAE PHARMACEUTICALS, INC. (US) 2013-09-19 — — WO disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed
US-4754024-A Fibre-reactive azo dyes containing vinylsulfonyl or analogous groups CIBA-GEIGY CORPORATION 1988-06-28 — — US disclosed
EP-0112285-B1 REACTIVE DYES, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1987-03-18 — — EP disclosed
EP-0026414-B1 WATER SOLUBLE MONOAZO COMPOUNDS, THEIR PREPARATION AND THEIR USE AS DYESTUFFS IN DYEING AND PRINTING TEXTILE MATERIALS, AS WELL AS THE AMINES PER SE CIBA-GEIGY AG (CH) 1985-04-10 — — EP disclosed
US-4467088-A USEFULL IN PREPARATION OF DYES CIBA-GEIGY CORPORATION (US) 1984-08-21 — — US disclosed
EP-0112285-A2 Reactive dyes, their preparation and their use CIBA-GEIGY AG (CH) 1984-06-27 — — EP disclosed
EP-0026414-A2 Water soluble monoazo compounds, their preparation and their use as dyestuffs in dyeing and printing textile materials, as well as the amines per se CIBA-GEIGY AG (CH) 1981-04-08 — — EP disclosed
US-4013631-A SYNTHETIC FIBERS BAYER AKTIENGESELLSCHAFT (DT) 1977-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 CA2 3892/4885CA1 2975/4885CA9 3995/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 CA2 3892/4885CA1 2975/4885CA9 3995/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 CA2 3601/4885CA1 2782/4885CA9 3658/4885
US-11180487-B2 Substituted cyanoindoline derivatives as NIK inhibitors NFKBIA, MAP3K14, IKBKG CA2 4294/4885CA1 4578/4885CA9 4148/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA2 2735/4885CA1 1571/4885CA9 2823/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 CA2 3892/4885CA1 2975/4885CA9 3995/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 CA2 2735/4885CA1 1571/4885CA9 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.